Drug intelligence / Profile preview

NTZ-1092

Development stage: Preclinical
Lead developer: NTZ Lab
Modality: Small Molecules

Overview

NTZ-1092 is a preclinical-stage small molecule drug candidate being developed by NTZ Lab for the treatment of central nervous system (CNS) disorders. It acts as a dual-acting monoamine oxidase inhibitor, targeting both the MAO-A and MAO-B enzymes to modulate monoamine neurotransmitter levels in the brain. The compound is currently being investigated for potential applications in neurodegenerative and psychiatric conditions, including Parkinson's disease, Alzheimer's disease, dementia, and depression.

Targets

MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on NTZ-1092.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTZ-1092.

Explore the full profile